The US Food and Drug Administration (FDA) has declined to approve ivonescimab plus platinum-containing chemotherapy for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) previously treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), citing insufficient evidence of an overall survival benefit.
Summit Therapeutics announced that it had received a Complete Response Letter for the biologics license application, following the anticipated November 14 FDA decision. According to the company, the FDA determined that the application could not be approved in its present form because substantial evidence of effectiveness had not been established without a statistically significant improvement in overall survival. The agency concluded that the progression-free survival benefit alone did not support a favorable benefit-risk profile.
The company describes ivonescimab as an investigational bispecific antibody targeting programmed cell death protein 1 and vascular endothelial growth factor, combining immune checkpoint blockade with inhibition of tumor angiogenesis.
The application was supported by HARMONi, a global phase 3, randomized, double-blind trial comparing ivonescimab plus platinum-containing chemotherapy with placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic nonsquamous NSCLC previously treated with a third-generation EGFR TKI. The trial met dual primary endpoints of progression-free survival, but the overall survival analysis showed a favorable trend without reaching statistical significance.
Summit stated that ivonescimab remains investigational and is not approved in the US, although it has marketing authorization in China. Development continues in other settings, including first-line NSCLC and colorectal cancer.
Source: Summit Therapeutics
